FDA Oks Foam Treatment for Adolescent Patients with Plaque Psoriasis
Calcipotriene is a synthetic vitamin D analog that has a similar receptor binding affinity as natural vitamin D.
Officials with the FDA have approved Mayne Pharma’s calcipotriene (Sorilux) foam, 0.005% for adolescent patients, according to the company.
1
Previously approved for adults,
the medication treats plaque psoriasis of the scalp and body.
21
Calcipotriene is a synthetic vitamin D analog that has a similar receptor binding affinity as natural vitamin D. The exact mechanism of action contributing to the clinical efficacy is unknown.
1
Psoriasis is a chronic disease of the immune system that affects approximately 7.5 million people each year
in the United States. Plaque psoriasis is the most common form of condition, affecting about 80% of patients with psoriasis.
1
“Topical products are the mainstay of treatment for plaque psoriasis patients and the foam delivery platform has a well-established reputation with dermatologists due to ease of application and lack of greasiness and stickiness, especially in hair-bearing areas and under clothing," said Mayne Pharma's CEO, Mr Scott Richards
, in a prepared statement.
1
Mayne recently launched a halobetasol propionate foam (Lexette), a potent topical corticosteroid also used to treat plaque psoriasis in adult patients. The calcipotriene foam is indicated for patients aged 12 years and older.
1
Calcipotriene foam was approved by the FDA in 2010 for patients age 18 years and older.
The earlier approval was based on evidence from a pair of 8-week placebo controlled clinical trials in patients with mild to moderate plaque psoriasis of the body and an 8-week placebo controlled clinical trial in patients with moderate plaque psoriasis of the scalp.
21
Additional data was obtained in a follow-on open label study in patients aged 12 to 17 years of age with psoriasis, according to Mayne.
1
References
- FDA Approves SORILUX(R) for Adolescent Plaque Psoriasis [news release]. Adelaide, Australia; May 22, 2019: Mayne Pharma. https://www.prnewswire.com/news-releases/fda-approves-soriluxr-for-adolescent-plaque-psoriasis-300854930.html. Accessed May 23, 2019.
- Sorilux. Prescribing Information. FDA website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022563s001lbl.pdf. Revised October 2010. Accessed May 23, 2019.
